Transcranial Magnetic Therapy (TMS) for Treatment of Perinatal Depression
NCT07928908, Not applicable, Active not recruiting, Rana Jawish
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Transcranial Magnetic Therapy (TMS) for Treatment of Perinatal Depression | ClinicalTrials.gov |
| NCT number | NCT07928908 | ClinicalTrials.gov |
| Status | Active not recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 100 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Rana Jawish | ClinicalTrials.gov |
| Conditions | Perinatal Depression | ClinicalTrials.gov |
| Interventions | Transcranial Magnetic Stimulation (TMS) | ClinicalTrials.gov |
| First posted | 2026-11-10 | ClinicalTrials.gov |
| Last updated | 2026-11-10 | ClinicalTrials.gov |
Registered outcomes 18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Retention Rate | 8 weeks post baseline | Proportion of participants who complete at least 20 TMS treatment sessions. | ClinicalTrials.gov |
| Secondary | Treatment Adherence Rate | 8 weeks post baseline | Proportion of participants who complete at least 80% of their scheduled TMS treatment sessions. | ClinicalTrials.gov |
| Secondary | Client Satisfaction Questionnaire (CSQ-8) | 8 weeks post baseline | Participant satisfaction with TMS treatment measured using the 8-item Client Satisfaction Questionnaire (CSQ-8). Total scores range from 8 to 32, with higher scores indicating greater satisfaction. A score of 24 or higher is the predefined acceptability threshold. | ClinicalTrials.gov |
| Secondary | Maternal adverse events | Throughout treatment (up to 8 weeks), with maternal medical record review 6 months (+/- 15 days) after delivery for participants enrolled during pregnancy | Incidence, severity, and relatedness of adverse events (AEs) and serious adverse events (SAEs) associated with TMS treatment. | ClinicalTrials.gov |
| Secondary | Fetal Adverse Events | Throughout treatment (up to 8 weeks post baseline) and up to delivery for participants enrolled during pregnancy | Incidence, severity, and relatedness of adverse events (AEs) and serious adverse events (SAEs) related to the fetus. | ClinicalTrials.gov |
| Secondary | Neonatal adverse events | birth through 6 months (+/- 15 days) postpartum | Incidence, severity, and relatedness of adverse events (AEs) and serious adverse events (SAEs) related to the infant from birth through 6 months postpartum for participants enrolled during pregnancy | ClinicalTrials.gov |
| Other | Change in Montgomery-Åsberg Depression Rating Scale (MADRS) | Baseline, after every 5 treatments (once/week for up to 8 weeks), and 1 month after treatment | Change in clinician-rated depressive symptoms measured using the Montgomery-Åsberg Depression Rating Scale (MADRS). Total scores range from 0 to 60, with higher scores indicating greater depression severity. | ClinicalTrials.gov |
| Other | Change in Edinburgh Postnatal Depression Scale (EPDS) | Screening, baseline, after every 5 treatments (once/week for up to 8 weeks), and 1-month follow-up | Change in depressive symptoms measured using the 10-item Edinburgh Postnatal Depression Scale (EPDS). Scores range from 0 to 30, with higher scores indicating greater depressive symptom severity. | ClinicalTrials.gov |
| Other | Change in Quick Inventory of Depressive Symptomatology (QIDS) | Baseline, daily after each TMS treatment, and 1-month follow-up | Change in depressive symptoms measured using the Quick Inventory of Depressive Symptomatology (QIDS). Total scores for the 16-item version range from 0 to 27, with higher scores indicating more severe depression. | ClinicalTrials.gov |
| Other | Change in Generalized Anxiety Disorder scale (GAD-7) | Baseline, after every 5 treatments (once/week for up to 8 weeks), and 1-month follow-up | Change in anxiety severity measured using the 7-item Generalized Anxiety Disorder scale (GAD-7). Scores range from 0 to 21, with higher scores indicating more severe anxiety. | ClinicalTrials.gov |
| Other | Change in Ruminative Responses Scale (RRS) | Baseline, after every 5 treatments (once/week for up to 8 weeks), and 1-month follow-up | Change in repetitive negative thinking measured using the Ruminative Responses Scale (RRS). The 22-item scale assesses rumination related to depressive symptoms, self-reflection, and brooding. Higher scores indicate greater rumination. | ClinicalTrials.gov |
| Other | Change in Pittsburgh Sleep Quality Index (PSQI) | Baseline, after every 5 treatments (once/week for up to 8 weeks), and 1-month follow-up | Change in sleep quality measured using the Pittsburgh Sleep Quality Index (PSQI). Global scores range from 0 to 21, with higher scores indicating poorer sleep quality. | ClinicalTrials.gov |
| Other | Change in PTSD Checklist for DSM-5 (PCL-5) | Baseline, after every 5 treatments (once/week for up to 8 weeks), and 1-month follow-up | Change in posttraumatic stress symptoms measured using the PTSD Checklist for DSM-5 (PCL-5). Scores range from 0 to 80, with higher scores indicating greater symptom severity. | ClinicalTrials.gov |
| Other | Change in World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0) | Baseline, end of treatment (up to week 8), and 1-month follow-up | Change in functional impairment measured using the World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0). Higher scores indicate greater disability or difficulty with daily functioning. | ClinicalTrials.gov |
| Other | Change in Maternal Antenatal/Postnatal Attachment Scale (MAAS/MPAS) | Baseline, end of treatment (up to week 8), and 1-month follow-up | The MAAS and MPAS are 19-item self-report questionnaires assessing maternal emotional attachment to the fetus during pregnancy (MAAS) and to the infant following birth (MPAS). The MAAS evaluates the quality and intensity of maternal attachment, while the MPAS assesses attachment quality, pleasure in interaction, and absence of hostility. Both scales yield total scores ranging from 19 to 95, with higher scores indicating stronger, more positive maternal attachment. Lower scores suggest greater difficulties with maternal-fetal or maternal-infant bonding. | ClinicalTrials.gov |
| Other | Montgomery-Åsberg Depression Rating Scale (MADRS) Response Rate | After 20 TMS sessions (week 4), end of treatment (up to 8 weeks from baseline), and 1-month follow-up | Proportion of participants achieving at least a 50% reduction in depressive symptom severity relative to baseline, assessed using Montgomery-Åsberg Depression Rating Scale (MADRS). | ClinicalTrials.gov |
| Other | Montgomery-Åsberg Depression Rating Scale (MADRS) Remission Rate | After 20 TMS sessions (week 4), end of treatment (up to 8 weeks from baseline), and 1-month follow-up | Proportion of participants meeting remission criteria, defined as MADRS score ≤10. | ClinicalTrials.gov |
| Other | Durability of Montgomery-Åsberg Depression Rating Scale (MADRS) change | End of treatment (up to 8 weeks from baseline) and 1-month follow-up | Maintenance of improvement in depressive symptoms, assessed by comparing depression severity at treatment completion with Montgomery-Åsberg Depression Rating Scale (MADRS) scores obtained one month after the final TMS session. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)